Breast cancer female

20 trials 7 recruiting MedDRA PT
20 Registered trials
7 Recruiting
13 Unique sponsors
19 Unique IMPs
8 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 10
— ATC code not specified 7
A Gastroenterology (ATC A) 1
J Anti-infectives (ATC J) 1
H Endocrinology (ATC H) 1
V Various (ATC V) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 7 substances
Antibody-drug conjugate (ADC) 2 substances
SERD 2 substances
Platinum compound 2 substances
Checkpoint inhibitor (PD-1) 1 substance
CDK inhibitor 1 substance
Macrolide / aminoglycoside 1 substance
Tetracycline 1 substance
Antimetabolite 1 substance
Anthracycline 1 substance
Phase III: 10 Phase II: 5 Phase IV: 4 Phase I (First in Human): 1

Filter these 20 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 20 trials

Phase III

10 trials
  • AstraZeneca AB Commercial
    CAPIVASERTIB; FULVESTRANT
    2023-505042-25-00 7 countries 2020 n=366
    Ended
  • WSG Westdeutsche Studiengruppe GmbH Commercial
    IMP not specified
    2023-509242-35-00 3 countries 2020 n=1,624
    Ended
  • WSG Westdeutsche Studiengruppe GmbH Commercial
    RIBOCICLIB
    2024-515769-32-00 1 country 2019 n=1,684
    Ended
  • WSG Westdeutsche Studiengruppe GmbH Commercial
    PEMBROLIZUMAB; SACITUZUMAB GOVITECAN
    2024-516734-35-00 1 country n=690
    Pending
  • WSG Westdeutsche Studiengruppe GmbH Commercial
    ELACESTRANT; RIBOCICLIB
    2025-522484-15-00 3 countries 2026 n=1,520
    Recruiting
  • GBG Forschungs GmbH Academic
    CAPECITABINE; CARBOPLATIN; CISPLATIN; SACITUZUMAB GOVITECAN
    2023-510390-33-00 6 countries 2020 n=1,386
    Ended
  • Karolinska Institutet Academic
    TAMOXIFEN
    2025-522240-40-00 1 country 2026 n=1,100
    Recruiting
  • Unicancer Academic
    DOXORUBICIN HYDROCHLORIDE
    2024-516996-34-00 2 countries 2012 n=1,989
    Ended
  • UZ Leuven Academic
    OXYTOCIN
    2024-519383-40-00 1 country n=60
    Pending
  • WSG Westdeutsche Studiengruppe GmbH Academic
    CAPIVASERTIB
    2024-511392-15-00 3 countries 2025 n=250
    Recruiting

Phase II

5 trials
  • WSG Westdeutsche Studiengruppe GmbH Commercial
    PEMBROLIZUMAB; SACITUZUMAB GOVITECAN
    2023-508787-29-00 1 country 2024 n=348
    Recruiting
  • WSG Westdeutsche Studiengruppe GmbH Commercial
    IMP not specified
    2024-514458-61-01 1 country 2024 n=705
    Ended
  • Azienda Ospedaliero Universitaria Pisana Academic
    AZITHROMYCIN DIHYDRATE; DOXYCYCLINE HYCLATE; SODIUM ASCORBATE
    2024-517993-94-00 1 country n=90
    Pending
  • Institut fuer Frauengesundheit GmbH Academic
    IMP not specified
    2024-519350-37-00 1 country n=89
    Ended
  • Karolinska University Hospital Academic
    GALLIUM (68GA) TEZATABEP MATRAXETAN; TRASTUZUMAB DERUXTECAN
    2024-512721-89-00 1 country n=70
    Pending

Phase IV

4 trials
  • Azienda Ospedaliero-Universitaria Policlinico Umberto I Academic
    IMP not specified
    2024-513251-32-00 1 country n=173
    Not authorised
  • Fundacion Ribera Salud Academic
    GADOPICLENOL
    2025-521810-24-00 1 country 2025 n=30
    Ended
  • Institut fuer Frauengesundheit GmbH Academic
    IMP not specified
    2022-500764-35-00 1 country 2022 n=2,000
    Recruiting
  • Rita Fior Academic
    IMP not specified
    2023-509598-22-01 1 country 2025 n=276
    Recruiting

Phase I (First in Human)

1 trial
  • Daiichi Sankyo Inc. Commercial
    DS-3939A
    2023-507937-14-00 3 countries 2025 n=207
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
WSG Westdeutsche Studiengruppe GmbH Commercial 7 Phase II, Phase III 3
Institut fuer Frauengesundheit GmbH Academic 2 Phase II, Phase IV 1
AstraZeneca AB Commercial 1 Phase III 0
Daiichi Sankyo Inc. Commercial 1 Phase I (First in Human) 1
Azienda Ospedaliero Universitaria Pisana Academic 1 Phase II 0
Karolinska University Hospital Academic 1 Phase II 0
GBG Forschungs GmbH Academic 1 Phase III 0
Karolinska Institutet Academic 1 Phase III 1
Unicancer Academic 1 Phase III 0
UZ Leuven Academic 1 Phase III 0
Azienda Ospedaliero-Universitaria Policlinico Umberto I Academic 1 Phase IV 0
Fundacion Ribera Salud Academic 1 Phase IV 0
Rita Fior Academic 1 Phase IV 1
New trials by year
2019
1
2020
3
2022
1
2024
2
2025
4
2026
2
← All indication landscapes